The Cancer Drug Development Forum – CDDF is the platform for all stakeholders involved in the development of cancer drugs.

ACCELERATE & EMA Paediatric Strategy Forum

Paediatric Strategy Forum for Anaplastic Lymphoma Kinase (ALK) Inhibition in Paediatric Malignancies
by CDDF – SIOPE – ITCC, in London, UK – 30 & 31 January 2017

The objective of this multi-stakeholder Paediatric Strategy Forum was to provide an opportunity for interaction and discussion between all stakeholders (regulators, pharmaceutical companies, clinical and researcher academics and patient representatives) on topics requiring open discussion or being identified as a hurdle or a problem from an industry and/or an academia standpoint in drug development in children and adolescents.

The Forum aimed to facilitate a strategy for development of drugs in a mechanism of action-informed programme focusing on a disease or a target.


The programme has discussed the epidemiology, clinical features, biology and therapeutic needs of the ALK driven paediatric tumours, followed by reviewing potential targets and then all ALK inhibitors in development and data from all paediatric clinical trials completed or in progress whether pharma or academic sponsored.


European Medicines Agency (EMA)
03-E Meeting room, 3rd floor
30 Churchill Pl, Canary Wharf, London E14 5EU, UK
Phone: +44 20 3660 6000


Should you have any questions then please do not hesitate to contact the meeting secretariat:

ACCELERATE Secretariat
Avenue E. Mounier 83 – 1200 Brussels, Belgium
Phone: +32 (0)2 775 02 12

ORGANISED BY: the ACCELERATE platform (, a joint initiative by the Innovative Therapy for Children with Cancer Consortium (ITCC), the European Society of Paediatric Oncology (SIOPE), the Cancer Drug Development Forum (CDDF) and the European Medecines Agency (EMA).

Cancer Drug Development Forum asbl
Registered office: c/o BLSI, Clos Chapelle-aux-Champs 30, 1200 Woluwe Saint Lambert, Belgium
Register of legal entities: the French Speaking Enterprise Court in Brussels
Enterprise number: 738.523.752
Tel: +32 2 880 62 70